BRPI0110801B8 - análogos antitumorais de et-743, composição farmacêutica compreendendo os mesmos e uso dos referidos análogos - Google Patents

análogos antitumorais de et-743, composição farmacêutica compreendendo os mesmos e uso dos referidos análogos

Info

Publication number
BRPI0110801B8
BRPI0110801B8 BRPI0110801A BRPI0110801B8 BR PI0110801 B8 BRPI0110801 B8 BR PI0110801B8 BR PI0110801 A BRPI0110801 A BR PI0110801A BR PI0110801 B8 BRPI0110801 B8 BR PI0110801B8
Authority
BR
Brazil
Prior art keywords
analogues
antitumor
same
pharmaceutical composition
group
Prior art date
Application number
Other languages
English (en)
Inventor
Rodriguez Alberto
Cuevas Carmen
Manzanares Ignacio
Jesus Martin Maria
Perez Marta
Munt Simon
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0110801A publication Critical patent/BR0110801A/pt
Publication of BRPI0110801B1 publication Critical patent/BRPI0110801B1/pt
Publication of BRPI0110801B8 publication Critical patent/BRPI0110801B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"análogos antitumorais de et-743". a invenção refere-se a compostos antitumorais que têm a estrutura de ecteinascidina de anel fundido de cinco membros da fórmula (xiv). os compostos presentes carecem de um grupo de ponte 1,4 como visto nas ecteinascidinas. eles têm na posição do c-1 um substituinte selecionado entre um grupo aminometileno opcionalmente protegido ou derivado ou um grupo hidroximetileno opcionalmente protegido ou derivado.
BR0110801-8 1999-05-14 2001-05-15 análogos antitumorais de et-743, composição farmacêutica compreendendo os mesmos e uso dos referidos análogos BRPI0110801B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911345.8A GB9911345D0 (pt) 1999-05-14 1999-05-14
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof
GBPCT/GB00/01852 2000-05-15

Publications (3)

Publication Number Publication Date
BR0110801A BR0110801A (pt) 2003-02-11
BRPI0110801B1 BRPI0110801B1 (pt) 2018-02-27
BRPI0110801B8 true BRPI0110801B8 (pt) 2021-05-25

Family

ID=42632476

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0010559A BRPI0010559B8 (pt) 1999-05-14 2000-05-15 processo hemissintético e compostos intermediários
BR0110443-8 BRPI0110443B8 (pt) 1999-05-14 2001-05-15 etapas processuais na produção de um composto de ecteinascidina
BR0110801-8 BRPI0110801B8 (pt) 1999-05-14 2001-05-15 análogos antitumorais de et-743, composição farmacêutica compreendendo os mesmos e uso dos referidos análogos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0010559A BRPI0010559B8 (pt) 1999-05-14 2000-05-15 processo hemissintético e compostos intermediários
BR0110443-8 BRPI0110443B8 (pt) 1999-05-14 2001-05-15 etapas processuais na produção de um composto de ecteinascidina

Country Status (29)

Country Link
US (3) US7241892B1 (pt)
EP (1) EP1185536B1 (pt)
JP (1) JP4445136B2 (pt)
KR (1) KR100834601B1 (pt)
CN (3) CN1229382C (pt)
AR (1) AR035842A1 (pt)
AT (1) ATE283273T1 (pt)
AU (2) AU775580B2 (pt)
BG (1) BG65896B1 (pt)
BR (3) BRPI0010559B8 (pt)
CA (2) CA2372058C (pt)
CY (1) CY1108095T1 (pt)
CZ (3) CZ303536B6 (pt)
DE (1) DE60016209T2 (pt)
DK (1) DK1185536T3 (pt)
ES (2) ES2233367T3 (pt)
HU (1) HU230646B1 (pt)
MX (1) MXPA01011631A (pt)
MY (1) MY130271A (pt)
NO (2) NO322016B1 (pt)
NZ (1) NZ515424A (pt)
PL (1) PL226890B1 (pt)
PT (1) PT1185536E (pt)
RU (1) RU2237063C9 (pt)
SI (2) SI1185536T1 (pt)
SK (2) SK287835B6 (pt)
TR (1) TR200103273T2 (pt)
UA (1) UA75333C2 (pt)
WO (3) WO2000069862A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139607A0 (en) 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
KR100886496B1 (ko) * 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
IL152125A (en) * 2000-05-15 2008-04-13 Pharma Mar Sa Process for the manufacture of ecteinascidin derivatives
JP2004529074A (ja) 2000-11-03 2004-09-24 プレジデント アンド フェロウズ オブ ハーバード カレッジ サフラマイシン、そのアナログ、およびその使用
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
AU2009248039B2 (en) * 2008-05-16 2014-07-31 Pharma Mar, S.A. Multiple myeloma treatments
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
WO2011147828A1 (en) 2010-05-25 2011-12-01 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) * 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法
CN117659032B (zh) * 2022-08-29 2026-06-19 南通诺泰生物医药技术有限公司 海鞘素类衍生物的中间体及其的合成方法
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
CN121986103A (zh) 2023-10-09 2026-05-05 法马马有限公司 用于制造海鞘素化合物的合成方法
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin
TW202610629A (zh) 2024-07-26 2026-03-16 西班牙商瑪製藥股份有限公司 用於製造海鞘素化合物的合成方法
CN119613425B (zh) * 2024-10-31 2026-04-03 深圳创元生物医药科技有限公司 一种曲贝替定五环核心骨架的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) * 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
IL139607A0 (en) 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
SK287835B6 (sk) 2011-12-05
CZ20023751A3 (en) 2004-05-12
BRPI0110443B1 (pt) 2018-06-26
CZ304966B6 (cs) 2015-02-18
WO2001087894A1 (en) 2001-11-22
NZ515424A (en) 2004-06-25
CN1211386C (zh) 2005-07-20
EP1185536B1 (en) 2004-11-24
NO20025186D0 (no) 2002-10-29
DK1185536T3 (da) 2005-04-04
JP2002544280A (ja) 2002-12-24
CA2372058A1 (en) 2000-11-23
CN1360588A (zh) 2002-07-24
NO20015547D0 (no) 2001-11-13
US7241892B1 (en) 2007-07-10
PL226890B1 (pl) 2017-09-29
WO2001087895A1 (en) 2001-11-22
PL353002A1 (en) 2003-09-22
SI1185536T1 (en) 2005-06-30
CA2372058C (en) 2010-10-26
RU2237063C2 (ru) 2004-09-27
EP1185536A2 (en) 2002-03-13
MXPA01011631A (es) 2002-07-30
HU230646B1 (hu) 2017-05-29
CZ20023746A3 (cs) 2003-04-16
NO20015547L (no) 2002-01-14
WO2000069862A2 (en) 2000-11-23
MY130271A (en) 2007-06-29
US7524956B2 (en) 2009-04-28
KR100834601B1 (ko) 2008-06-02
UA75333C2 (uk) 2006-04-17
CA2406095A1 (en) 2001-11-22
NO20025186L (no) 2003-01-14
SK16502001A3 (sk) 2002-06-04
CZ20014102A3 (cs) 2002-06-12
ATE283273T1 (de) 2004-12-15
BG107301A (bg) 2003-07-31
CN1440414A (zh) 2003-09-03
SK15272002A3 (sk) 2003-06-03
US20080045713A1 (en) 2008-02-21
CN1229382C (zh) 2005-11-30
AU5649601A (en) 2001-11-26
CN1441805A (zh) 2003-09-10
BRPI0110801B1 (pt) 2018-02-27
CY1108095T1 (el) 2014-02-12
AR035842A1 (es) 2004-07-21
CA2406095C (en) 2010-02-16
RU2237063C9 (ru) 2008-10-10
NO328301B1 (no) 2010-01-25
CZ303536B6 (cs) 2012-11-21
ES2233367T3 (es) 2005-06-16
DE60016209D1 (de) 2004-12-30
TR200103273T2 (tr) 2002-04-22
BR0110801A (pt) 2003-02-11
AU4597300A (en) 2000-12-05
BG65896B1 (bg) 2010-04-30
HK1047432A1 (en) 2003-02-21
CN100475822C (zh) 2009-04-08
DE60016209T2 (de) 2005-12-15
AU775580B2 (en) 2004-08-05
BRPI0010559B8 (pt) 2021-05-25
BRPI0110443B8 (pt) 2021-05-25
SK287879B6 (sk) 2012-02-03
KR20020021636A (ko) 2002-03-21
BRPI0010559B1 (pt) 2016-08-30
ES2231486T3 (es) 2005-05-16
WO2000069862A3 (en) 2001-03-22
NO322016B1 (no) 2006-08-07
SI1287004T1 (sl) 2005-12-31
BR0010559A (pt) 2002-07-02
US20040002602A1 (en) 2004-01-01
BR0110443A (pt) 2003-04-08
CZ304973B6 (cs) 2015-02-25
HUP0201188A2 (en) 2002-07-29
JP4445136B2 (ja) 2010-04-07
PT1185536E (pt) 2005-04-29

Similar Documents

Publication Publication Date Title
BR0110801A (pt) Análogos antitumorais de et-743
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
BRPI0116237B8 (pt) "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
ATE249486T1 (de) Wässrige reaktive spachtelmassen (i)
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
BR0207715A (pt) Compostos, composições farmacêuticas, e uso de um ou mais compostos
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
IL152126A0 (en) Analogs of ecteinascidin and pharmaceutical compositions containing the same
BR0111222A (pt) Derivados fosfonados de glicopeptìdeo
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
BR9810495A (pt) Composição farmacêutica
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
TR200101412T2 (tr) Yeni bileşikler.
EE200300254A (et) Heterotsüklilised ühendid, millel on antibakteriaalne toime, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
DE69527696D1 (de) Kristalline Paclitaxel Hydrate
TR200003108T2 (tr) İlaç kompozisyonları
BR9909486A (pt) Compostos calcilìticos
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
DE69929703D1 (de) Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
YU11401A (sh) Lokalne farmaceutske kompozicije koje sadrže nimesulid
EE04157B1 (et) Sünteetilised polüsahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
ATE249740T1 (de) Orale antimikrobielle und desodoriende zusammensetzungen
SE8302979L (sv) Piperazinderivat, deras framstellning och farmaceutiska kompositioner innehallande dessa
DE69805860D1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2670 DE 08/03/2022 POR TER SIDO INDEVIDA, TENDO EM VISTA A RETIFICACAO DA VIGENCIA DA PATENTE PARA 20 ANOS CONTADOS DO DEPOSITO.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/05/2021